SRPT - サレプタ・セラピュ―ティックス （Sarepta Therapeutics Inc.） サレプタ・セラピュ―ティックスSRPTのチャート
SRPTの企業情報
| symbol | SRPT |
|---|---|
| 会社名 | Sarepta Therapeutics Inc （サレプタ・セラピュ―ティックス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 サレプタ・セラピューティクス（Sarepta Therapeutics Inc.）はバイオ医薬品会社である。同社は希少神経筋疾患の治療用のリボ核酸（RNA）標的治療法の発見・開発に従事する。同社はデュシェンヌ型筋ジストロフィー（DMD）患者の治療法の発見・開発・製造・提供を通じて運営する。同社はその疾患修飾性DMD薬候補の開発に焦点を当てる。同社はエキソン51のスキッピングを受けやすいDMD遺伝子の突然変異が確認された患者のDMD治療について示された製品EXONDYS 51の承認が早まった。EXONDYS 51は、「eteplirsen」の名で臨床試験中に研究されている。その次世代のホスホロジアミデートモルホリノオリゴマー（PMO）ベースの化合物は、標準的なワトソン - クリック核酸塩基対形成によってRNAの相補的配列に結合する合成化合物である。PMOに基づく化学は、ペプチド共役PMO（PPMO）、PMO-XおよびPMOplusである。 サレプタ・セラピュ―ティックスは米国のバイオ医薬品会社。奇病と伝染病両方の治療に用いる独自のRNA（リボ核酸）ベ―スの治療法発見と開発を手掛ける。また、マ―ルブルグ出血熱ウイルスのための薬剤候補AVI-7288や、H1N1インフルエンザ薬候補、エボラ出血熱ウィルスの薬剤候補の開発にも従事する。 Sarepta Therapeutics Inc. is leading a revolution in precision genetic medicine and every day is an opportunity to change the lives of people living with raredisease. The Company has built an impressive position in Duchenne muscular dystrophy (DMD) and in gene therapies for limb-girdle muscular dystrophies (LGMDs), mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and other CNS-related disorders, with more than 40 programs in various stages of development. The Company's programs and research focus span several therapeutic modalities, including RNA, gene therapy and gene editing. |
| 本社所在地 | 215 First Street Suite 415 Cambridge MA 02142 USA |
| 代表者氏名 | M. Kathleen Behrens M.キャスリーン・ベーレンス |
| 代表者役職名 | Independent Chairwoman of the Board |
| 電話番号 | +1 617-274-4000 |
| 設立年月日 | 29403 |
| 市場名 | NASDAQ National Market System |
| ipoyear | ―年 |
| 従業員数 | 255人 |
| url | www.sarepta.com |
| nasdaq_url | https://www.nasdaq.com/symbol/srpt |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -167.82400 |
| 終値（lastsale） | 131.18 |
| 時価総額（marketcap） | 8715914294.36 |
| 時価総額 | 時価総額（百万ドル） 8917.899 |
| 売上高 | 売上高（百万ドル） 241.36400 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 8408.194 |
| 当期純利益 | 当期純利益（百万ドル） -216.36200 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Sarepta Therapeutics Inc revenues increased from $51.4M to $138.1M. Net loss totaled $144.6M vs. income of $21M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects Gain from sale of Priority Review Vouche decrease from $125M (income) to $0K Research and development- other increase of 93% to $162M (expense). |
SRPTのテクニカル分析
SRPTのニュース
This Is What Whales Are Betting On Sarepta Therapeutics 2023/05/03 19:02:09 Benzinga
Someone with a lot of money to spend has taken a bullish stance on Sarepta Therapeutics (NASDAQ: SRPT ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with SRPT, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 14 uncommon options trades for Sarepta Therapeutics. This isn''t normal. The overall sentiment of these big-money traders is split between 57% bullish and 42%, bearish. Out of all of the special options we uncovered, 6 are puts, for a total amount of $449,130, and 8 are calls, for a total amount of $470,774. What''s The Price Target? Taking into … Full story available on Benzinga.com
Sarepta Therapeutics (SRPT) Q1 2023 Earnings Call Transcript 2023/05/03 04:00:25 The Motley Fool
SRPT earnings call for the period ending March 31, 2023.
Sarepta Therapeutics, Inc. (SRPT) Q1 2023 Earnings Call Transcript 2023/05/03 00:52:02 Seeking Alpha
Sarepta Therapeutics, Inc. (NASDAQ:NASDAQ:SRPT) Q1 2023 Earnings Conference Call May 2, 2023 4:30 PM ETCompany ParticipantsMary Jenkins – Associate Director-Investor RelationsDoug Ingram –…
Sarepta Therapeutics Q1 Loss Increases, but beats estimates 2023/05/02 20:36:00 Finanz Nachrichten
WASHINGTON (dpa-AFX) - Sarepta Therapeutics (SRPT) revealed Loss for its first quarter that increased from last year and missed the Street estimates.The company''s earnings came in at -$516.76 mill…
Sarepta Therapeutics: Q1 Earnings Snapshot 2023/05/02 20:23:23 WTOP
CAMBRIDGE, Mass. (AP) — CAMBRIDGE, Mass. (AP) — Sarepta Therapeutics Inc. (SRPT) on Tuesday reported a loss of $516.8 million…
Buy - Sarepta Therapeutics Receives New Coverage from Analysts at Citigroup 2023/04/05 08:01:12 Business Mag
Citigroup began coverage on shares of Sarepta Therapeutics in a research report report published on Tuesday, The Fly reports. The brokerage issued a buy rating and a $179.00…
Sarepta Therapeutics (NASDAQ:SRPT) Receives New Coverage from Analysts at Citigroup 2023/04/05 07:58:41 The AM Reporter
Citigroup began coverage on shares of Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) in a research report report published on Tuesday, The Fly reports. The brokerage issued a buy rating and a $179.00 price objective on the biotechnology company’s stock. Other equities research analysts also recently issued reports about the company. Oppenheimer decreased their price objective […]
Sarepta gains as Citi issues Buy despite AdCom for gene therapy 2023/04/04 12:12:59 Seeking Alpha
Sarepta Therapeutics (SRPT) shares gained Tuesday after Citi initiated its coverage with a Buy citing a compelling setup ahead of an FDA AdCom meeting. Read more here.
FDA Hands Sarepta A Positive Catalyst 2023/03/28 11:30:00 Seeking Alpha
Sarepta Therapeutics'' gene therapy has a novel mechanism for increasing a different type of dystrophin to treat a rare disease. Read more on FDA''s recent decision.
SRPT INVESTOR NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - SRPT 2023/03/25 18:30:00 Kwhen Finance
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday 2023/03/01 15:18:41 Benzinga
U.S. stocks traded lower, with the Dow Jones … Full story available on Benzinga.com
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy 2023/03/01 15:01:22 Investor''s Business Daily
Sarepta could snag an accelerated approval for its muscular dystrophy gene therapy, analysts suggested Wednesday as SRPT stock rocketed.
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today? 2023/03/01 14:49:58 InvestorPlace
Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade.